Bioxytran Reports Strong Phase 2 Results for ProLectin-M

Bioxytran ( (BIXT) ) has issued an announcement.

On Feb. 11, 2026, Bioxytran reported positive topline data from a completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization trial of its oral antiviral candidate ProLectin-M in patients with acute viral infection. The 38-subject study showed complete elimination of viral load in 100% of treated patients by Day 7 versus placebo, with no viral rebounds observed over a 14-day post-treatment follow-up, and viral non-detection emerging as early as Day 3.

The trial confirmed and refined earlier Phase 2 findings, identifying a four-tablet daily dose while demonstrating rapid and sustained viral clearance using RT-PCR–based virologic assessments. These results strengthen Bioxytran’s positioning in the antiviral space by supporting ProLectin-M’s novel extracellular, galectin-antagonist mechanism as a broad-range antiviral approach and provide a foundation for late-stage development plans and potential expansion into additional viral indications.

More about Bioxytran

Bioxytran, Inc. is a clinical-stage biotechnology company developing novel carbohydrate-based therapeutics targeting significant unmet medical needs in virology and other disease areas. Its lead program, ProLectin-M, is being developed as a potential broad-spectrum antiviral therapeutic aimed at blocking viral entry via galectin antagonism rather than traditional intracellular replication targets.

The company focuses on leveraging carbohydrate-based chemistry and the emerging field of glycovirology to create new antiviral treatment modalities. Bioxytran’s market focus centers on acute viral infections where rapid viral clearance and reduced dependence on immune activation could offer clinical and economic benefits over existing therapies.

Average Trading Volume: 171,391

Technical Sentiment Signal: Sell

Current Market Cap: $5.09M

Learn more about BIXT stock on TipRanks’ Stock Analysis page.